These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34686147)

  • 1. The liver steatosis severity and lipid characteristics in primary biliary cholangitis.
    Zhang Y; Hu X; Chang J; Chen J; Han X; Zhang T; Shen J; Shang N; Han J; Wang H; Kang W; Meng F
    BMC Gastroenterol; 2021 Oct; 21(1):395. PubMed ID: 34686147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis.
    Minuk GY; Iliant V; Zhou N; Kaita KD; Wong SG; Peretz D; Uhanova J
    Liver Int; 2018 Jun; 38(6):1110-1116. PubMed ID: 29193593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of primary biliary cholangitis on non-alcoholic fatty liver disease.
    Iluz-Freundlich D; Uhanova J; Grubert Van Iderstine M; Minuk GY
    Eur J Gastroenterol Hepatol; 2021 Apr; 33(4):565-570. PubMed ID: 32541239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of lower limb atherosclerosis is linked with the gut-liver axis in patients with primary biliary cholangitis.
    Ponziani FR; Nesci A; Caputo C; Salvatore L; Picca A; Del Chierico F; Paroni Sterbini F; Marzetti E; Di Giorgio A; Santoro L; Putignani L; Gasbarrini A; Santoliquido A; Pompili M
    Liver Int; 2023 Feb; 43(2):370-380. PubMed ID: 36287108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of the monocyte to high-density lipoprotein cholesterol ratio and alkaline phosphatase-to-platelet ratio in primary biliary cholangitis.
    Lao Y; Li X; Zhou W; Zhu H; Jiang Y; Li S; Jin M; Wang J
    Medicine (Baltimore); 2023 Oct; 102(41):e35454. PubMed ID: 37832129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
    Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis.
    Loaeza-Del Castillo AM; Gaytán-Santillán A; López-Tello A; Merit MV; Milke-García MDP; Flores-Rodríguez J; Alvirde-García U
    Ann Hepatol; 2019; 18(6):879-882. PubMed ID: 31506216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differential characteristics of AMA-M2 autoantibody in primary biliary cirrhosis and non-PBC patients].
    Sun L; Wang Y; Liu Y; Zhao Y; Zhang X; Wang Y; Zhao D; Zhang H; Ma Y
    Zhonghua Gan Zang Bing Za Zhi; 2015 May; 23(5):343-9. PubMed ID: 26192239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C.
    Valkov I; Ivanova R; Alexiev A; Antonov K; Mateva L
    J Clin Diagn Res; 2017 Aug; 11(8):OC15-OC20. PubMed ID: 28969178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis.
    Hernández-Pérez M; Riado D; Pena E; Méndez C; Pinedo F; Ramos P; Castillo P; Romero M; Fernández-Rodríguez C; Olveira A
    Aliment Pharmacol Ther; 2024 Sep; 60(5):613-619. PubMed ID: 38924185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.
    Sorokin A; Brown JL; Thompson PD
    Atherosclerosis; 2007 Oct; 194(2):293-9. PubMed ID: 17240380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
    Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
    J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease.
    Fukuo Y; Yamashina S; Sonoue H; Arakawa A; Nakadera E; Aoyama T; Uchiyama A; Kon K; Ikejima K; Watanabe S
    Hepatol Res; 2014 Sep; 44(9):1026-36. PubMed ID: 24299564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method.
    Zhuang Z; Qu H; Yang W; Liu J; Wang F; Liu Y; Ding J; Shi J
    Ann Hepatol; 2020; 19(3):313-319. PubMed ID: 31870745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An analysis of the serological characteristics of anti-mitochondrial M2 subtype in patients with drug-induced liver injury and primary biliary cholangitis].
    Sun LM; Yan HP; Lou JL; Wang Y; Zhao Y; Yu YH; Zhang HP; Liu YM
    Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):298-303. PubMed ID: 31082342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.